#Sovaldi

A photographer helps his mom get cured of hep C after reading Hep magazine.

More than 125,000 veterans will have received lifesaving cures by October 2018.

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

In a recent study of more than 600 HIV-positive adults, 93 percent were cured of hep C.

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

Among those without cirrhosis, treating for an additional four weeks is unnecessary.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Ending the epidemic is going to require addressing the fact that certain individuals are at high risk of reinfection after a cure.

Those for whom Mavyret did not work the first time had a high cure rate with this intensified retreatment regimen.

In a recent trial, 12 weeks of the drug combination worked well regardless of whether individuals had drug-resistant virus.

Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.

The drugmaker is accused of infringing on a patent held by rival Merck & Co. over its formulas for Sovaldi and Harvoni treatment.